“…In contrast to SSRIs targeting the serotonin transporter SERT, psychedelics exert their psychotropic effects via direct stimulation of specific receptors, in particular agonistic activity on the 5-HT2A receptor (psilocybin: Kometer, Schmidt, Jancke, & Vollenweider, 2013;LSD: Preller et al, 2018DMT: Valle et al, 2016) and/or sigma-1 receptors (DMT: Palhano-Fontes et al, 2015). Preliminary evidence in human studies supports significant symptom alleviation through psychedelics substances in various psychiatric disorders, including depression Watts, Day, Krzanowski, Nutt, & Carhart-Harris, 2017), obsessive-compulsive disorder (Moreno, Wiegand, Taitano, & Delgado, 2006;Wilcox, 2014), body dysmorphic disorder (Hanes, 1996), and eating disorders (Mills, Park, Manara, & Merriman, 1998;Renelli et al, 2018).…”